Compare · ABOS vs BIIB
ABOS vs BIIB
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.53B, about 172.5x ABOS ($171.2M).
- Over the past year, ABOS is up 121.5% and BIIB is up 53.0% - ABOS leads by 68.5 points.
- BIIB has been more active in the news (20 items in the past 4 weeks vs 10 for ABOS).
- BIIB has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- Biogen Inc.
- Price
- $2.37-0.21%
- $200.00+0.04%
- Market cap
- $171.2M
- $29.53B
- 1M return
- -5.01%
- -2.21%
- 1Y return
- +121.50%
- +53.04%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 20
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest ABOS
- Director Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)
- Director Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)
- Director Fountain Nathan B was granted 35,500 shares, increasing direct ownership by 186% to 54,550 units (SEC Form 4)
- Director Drapkin Kimberlee C was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Stalfort John A Iii was granted 35,500 shares, increasing direct ownership by 19% to 220,624 units (SEC Form 4)
- Director Porter Derrell was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Ives Jeffrey L. was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Golumbeski George was granted 35,500 shares (SEC Form 4)
- Director Stoppel Laura was granted 35,500 shares (SEC Form 4)
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest BIIB
- Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)
- Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)
- Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)
- Director Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)
- Director Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)
- Director Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)
- Director Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)
- Director Minor Lloyd was granted 1,505 shares, increasing direct ownership by 64% to 3,875 units (SEC Form 4)
- Director Freire Maria C was granted 2,005 shares, increasing direct ownership by 29% to 8,820 units (SEC Form 4)
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders